港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,793.042

+20.8101.17%

漲家數：4

跌家數：4

平家數：- -

市盈率：- -

高：1,835.570

開：1,770.415

低：1,747.549

收：1,772.232

資料載入中...

聯邦制藥附屬公司創新藥UBT251注射液獲FDA批准開展II期臨牀試驗

藥明生物(02269.HK)推全新微生物表達平臺EffiX

阿斯达克财经

基石藥業(02616.HK)治療實體瘤藥物臨牀試驗順利完成首例患者給藥

阿斯达克财经

藥明生物推出全新微生物表達平臺EffiX

基石藥業(02616)CS2009全球多中心I期臨牀試驗完成首例患者給藥

【基石藥業-B(02616.HK)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥】基石藥業-B(02616.HK)發佈公告，公司自主研發的PD-1/VEGF/CTLA-4三特異性抗體CS2009的全球多中心I期臨牀試驗順利完成首例患者給藥，未發生輸液反應或其他不良事件。

基石藥業-B(02616)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥

聯邦制藥(03933.HK)UBT251注射液獲美FDA批准新藥臨牀試驗

阿斯达克财经

聯邦制藥(03933)研發的UBT251 注射液 CKD 適應症獲美國 FDA 批准新藥臨牀試驗

康泰生物(300601.SZ)子公司收到吸附破傷風疫苗Ⅰ/Ⅲ期臨牀試驗總結報告

華東醫藥(000963.SZ)：多肽類人GLP-1受體和GIP受體的雙靶點長效激動劑HDM1005注射液臨牀試驗獲批

藥明康德將於3月17日審議年度業績及股息策略

康龍化成收盤上漲1.51%，滾動市盈率25.33倍，總市值477.27億元

康龍化成3月3日現1筆大宗交易成交金額1333.5萬元

新浪证券-红岸工作室

昭衍新藥(06127)截至2月末累計回購A股股份326.98萬股

智通财经网

【黑石擬收購日本臨牀研究機構CMIC六成權益或涉及數億美元】全球最大另類資產管理人黑石正收購一家專注於幫助製藥公司在日本進行臨牀試驗的公司CMIC Co.，反映其對日本老齡化人口健康需求的興趣日益增加。據悉，黑石同意收購CMIC Co. 60%股權，惟未有透露具體金額，僅指交易的價值可達數億美元。黑石日本私募股權主管Atsuhiko Sakamoto曾在訪問中表示，日本的臨牀試驗過程效率頗低，對比其他市場需時非常長。它們目前將簡化過程，可以更快介紹新藥到日本，而黑石可以從中作出貢獻。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1793.0419,"timestamp":1741334919514,"preClose":1772.232,"halted":0,"volume":105965997,"delay":0,"changeRate":0.011742,"change":20.809814,"pbRate":2.65369,"amount":2334342230,"amplitude":0.049667,"prevYearClose":1395.7731,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"turnoverRate":0.008873,"marketCap":381645564416,"floatMarketCap":165840598400,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1835.5696,"amplitude":0.049667,"preClose":1772.232,"low":1747.5487,"pbRate":"2.65369","latestPrice":1793.0419,"volume":105965997,"delay":0,"open":1770.415,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"sixtyDayClose":1337.64,"secType":"PLATE","market":"HK","turnoverRate":0.008873,"peRate":33.079805,"marketCap":381645564416,"floatMarketCap":165840598400,"timestamp":1741334919514,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":4,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516912266","title":"聯邦制藥附屬公司創新藥UBT251注射液獲FDA批准開展II期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516912266","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516912266?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 09:31","pubTimestamp":1741051903,"startTime":"0","endTime":"0","summary":"3月4日，联邦制药（03933）发布公告，近日公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局（FDA）批准，允许开展慢性肾脏病（CKD）适应症的II期临床试验。此前，该适应症已于2025年1月20日获得中国国家药品监督管理局的临床试验批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335652766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","BK1576","03933","BK1161","BK1583","BK1191","BK1141","03347"],"gpt_icon":0},{"id":"2516699110","title":"藥明生物(02269.HK)推全新微生物表達平臺EffiX","url":"https://stock-news.laohu8.com/highlight/detail?id=2516699110","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516699110?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 09:18","pubTimestamp":1741051080,"startTime":"0","endTime":"0","summary":"药明生物宣布推出创新技术平台EffiX，该平台基于大肠杆菌表达系统建立，旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA，通过提供全面且具有成本效益的CMC策略，简化工艺开发流程，可以满足从研究到商业化生产的各种项目服务需求，协助全球合作伙伴加速研发创新生物疗法。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421839/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0823426308.USD","02269","LU1880383366.USD","LU0140636845.USD","LU0348735423.USD","LU0856984785.SGD","LU0051755006.USD","LU0039217434.USD","LU0516422440.USD","LU0588546209.SGD","LU0327786744.USD","LU1242518857.USD","BK1141","LU0326950275.SGD","LU0516423091.SGD","LU0043850808.USD","LU0708995583.HKD","LU0456827905.SGD","LU0572944931.SGD","LU0456846285.SGD","LU2039709279.SGD","LU1242518931.SGD","LU1720050803.USD","LU1794554557.SGD","LU1688375341.USD","BK1610","LU0307460666.USD","LU0823426480.USD","BK1521","LU0516422952.EUR","LU0052750758.USD","LU0417516902.SGD","LU0348825331.USD","LU0417516738.SGD","LU0819121731.USD","IE00B0JY6N72.USD","LU0516423174.USD","LU0516422366.SGD","LU0320764599.SGD","SG9999002463.SGD","BK1576","SG9999002562.SGD","LU0181495838.USD","LU0359202008.SGD","LU0979878070.USD","BK1589","LU0359201612.USD"],"gpt_icon":0},{"id":"2516361696","title":"基石藥業(02616.HK)治療實體瘤藥物臨牀試驗順利完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516361696","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516361696?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 09:00","pubTimestamp":1741050000,"startTime":"0","endTime":"0","summary":"基石药业公布，其自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。临床前研究显示，CS2009的抗肿瘤活性优于潜在竞品。(港股报价延迟最少十五分钟。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421823/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1576","BK1574","BK1141","02616","03347","BK1161","BK1583"],"gpt_icon":0},{"id":"2516869507","title":"藥明生物推出全新微生物表達平臺EffiX","url":"https://stock-news.laohu8.com/highlight/detail?id=2516869507","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516869507?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:48","pubTimestamp":1741049328,"startTime":"0","endTime":"0","summary":"【药明生物推出全新微生物表达平台EffiX】药明生物（02269.HK）今日宣布，推出创新技术平台EffiXTM。该平台基于大肠杆菌表达系统建立，旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202503043335398947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456846285.SGD","LU0327786744.USD","LU1242518857.USD","LU1880383366.USD","LU0417516902.SGD","LU0516422952.EUR","LU0572944931.SGD","LU0359201612.USD","LU1242518931.SGD","BK1589","LU1688375341.USD","SG9999002562.SGD","BK1610","LU0348735423.USD","LU0320764599.SGD","LU0417516738.SGD","LU0516422440.USD","IE00B0JY6N72.USD","LU0307460666.USD","LU0819121731.USD","LU0516423091.SGD","LU0140636845.USD","LU0348825331.USD","LU0708995583.HKD","LU1794554557.SGD","LU0516422366.SGD","LU0856984785.SGD","LU0043850808.USD","02269","LU0326950275.SGD","LU0359202008.SGD","LU0039217434.USD","LU0823426480.USD","BK1141","LU0181495838.USD","LU0456827905.SGD","LU0051755006.USD","LU0588546209.SGD","LU2039709279.SGD","LU0052750758.USD","LU1720050803.USD","LU0823426308.USD","BK1576","SG9999002463.SGD","LU0516423174.USD","LU0979878070.USD","BK1521"],"gpt_icon":0},{"id":"2516269575","title":"基石藥業(02616)CS2009全球多中心I期臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269575","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269575?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:47","pubTimestamp":1741049275,"startTime":"0","endTime":"0","summary":"金吾财讯 | 基石药业(02616)公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954249","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","02616","BK1576","BK1141","03347","BK1574"],"gpt_icon":0},{"id":"2516984776","title":"【基石藥業-B(02616.HK)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥】基石藥業-B(02616.HK)發佈公告，公司自主研發的PD-1/VEGF/CTLA-4三特異性抗體CS2009的全球多中心I期臨牀試驗順利完成首例患者給藥，未發生輸液反應或其他不良事件。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516984776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516984776?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:10","pubTimestamp":1741047048,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04081048500557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02616","BK4023","LU1169589451.USD","BK1583","BK1161","LU1169590202.USD","BK1574","BK1576","PD","BK1141","03347"],"gpt_icon":0},{"id":"2516698610","title":"基石藥業-B(02616)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516698610","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516698610?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:06","pubTimestamp":1741046794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。目前，CS2009率先在澳大利亚开展多中心I期临床试验，未来将陆续扩展至中国及美国。据悉，CS2009是一款靶向PD-1、VEGFA及CTLA-4的三特异性分子，作为靶向大瘤种的三特异性抗体，具备同类首创/同类最优潜力。临床前数据显示，CS2009具有明显优于潜在竞品的抗肿瘤活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","02616","BK1161","LU1169589451.USD","03347","BK1141","LU1169590202.USD","BK1583","BK1576","PD","BK1574"],"gpt_icon":0},{"id":"2516250655","title":"聯邦制藥(03933.HK)UBT251注射液獲美FDA批准新藥臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516250655","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516250655?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 00:35","pubTimestamp":1741019700,"startTime":"0","endTime":"0","summary":"联邦制药(03933.HK) 公布，全资附属联邦生物科技(珠海横琴)自主研发的1类创新药UBT251注射液获美国药品监督管理局“FDA”许可，同意开展慢性肾脏病“CKD”适应症II期临床试验。此前，CKD适应症已获得中国国家药品监督管理局临床试验批准。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421743/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03933","BK1576","BK1141","BK1191","BK1583","03347"],"gpt_icon":0},{"id":"2516631305","title":"聯邦制藥(03933)研發的UBT251 注射液 CKD 適應症獲美國 FDA 批准新藥臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631305","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631305?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 22:18","pubTimestamp":1741011490,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 公布，近日，公司全资附属公司联邦生物科技有限公司自主研发的 1 类创新药 UBT251 注射液获得美国药品监督管理局许可，同意开展慢性肾脏病适应症 II 期临床试验。此前，CKD 适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。目前，成人 2 型糖尿病、超重或肥胖、CKD 等多个适应症已取得中国及美国两地药物临床试验批准，并已于中国率先进入临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","BK1576","BK1141","03347","03933"],"gpt_icon":0},{"id":"2516898026","title":"康泰生物(300601.SZ)子公司收到吸附破傷風疫苗Ⅰ/Ⅲ期臨牀試驗總結報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2516898026","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516898026?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 18:28","pubTimestamp":1740997699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司全资子公司北京民海生物科技有限公司(“民海生物”)近日收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告，民海生物研发的吸附破伤风疫苗临床研究阶段工作顺利完成。研究结果显示，民海生物研制的吸附破伤风疫苗应用于成人免疫具有良好的安全性和免疫原性。本次吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告的取得表明吸附破伤风疫苗具备了申报生产的必备条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","BK0201","BK0239","BK0046","300601","03347","159646"],"gpt_icon":0},{"id":"2516856686","title":"華東醫藥(000963.SZ)：多肽類人GLP-1受體和GIP受體的雙靶點長效激動劑HDM1005注射液臨牀試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2516856686","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516856686?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:47","pubTimestamp":1740995243,"startTime":"0","endTime":"0","summary":"据悉，HDM1005注射液是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类化学新药，是多肽类人GLP-1受体和GIP受体的双靶点长效激动剂。HDM1005注射液为多肽类人GLP-1受体和GIP受体的双靶点长效激动剂，GLP-1类产品具有减肥、降糖和心血管获益等作用，是相对成熟和安全的靶点。本次HDM1005注射液临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在内分泌治疗领域的核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK4590","BK1576","000963","BK1141","LU1969619763.USD","03347","BK0209","LU2328871848.SGD","BK4144","GLP","BK0187","BK1583","BK0188","BK0175","BK0183","BK0196"],"gpt_icon":0},{"id":"2516685550","title":"藥明康德將於3月17日審議年度業績及股息策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2516685550","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516685550?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:44","pubTimestamp":1740995064,"startTime":"0","endTime":"0","summary":"3月3日，药明康德（603259/02359）发布公告，将于2025年3月17日召开董事会会议，主要内容包括考虑和批准截至2024年12月31日的年度业绩及建议的末期股息（如有）。公告并未透露具体的财务数据或业绩变化，因此无法提供相关的数字信息。此次董事会会议的召开旨在审议公司整体的经营情况及未来的股东回报策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503033334901567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2045819591.USD","BK1576","LU1046422090.SGD","BK1141","LU2242644610.SGD","LU0052750758.USD","02359","BK1583","LU0708995583.HKD","LU2125910500.SGD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2516836896","title":"康龍化成收盤上漲1.51%，滾動市盈率25.33倍，總市值477.27億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516836896","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516836896?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:27","pubTimestamp":1740994020,"startTime":"0","endTime":"0","summary":"3月3日，康龙化成今日收盘26.84元，上涨1.51%，滚动市盈率PE达到25.33倍，总市值477.27亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均47.53倍，行业中值43.87倍，康龙化成排名第18位。消息面上，康龙化成10月30日接待中金证券等38家机构调研，上市公司接待人员包括首席财务官、董事会秘书李承宗。最新一期业绩显示，2024年三季报，公司实现营业收入88.17亿元，同比3.00%；净利润14.22亿元，同比24.82%，销售毛利率33.87%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/03172748487215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","300759","BK1141","03759","BK0216"],"gpt_icon":0},{"id":"2516688502","title":"康龍化成3月3日現1筆大宗交易 成交金額1333.5萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688502","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516688502?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 17:00","pubTimestamp":1740992400,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　3月3日，康龙化成收涨1.51%，收盘价为26.84元，发生1笔大宗交易，合计成交量50万股，成交金额1333.5万元。　　第1笔成交价格为26.67元，成交50.00万股，成交金额1,333.50万元，溢价率为-0.63%，买方营业部为机构专用，卖方营业部为中信证券华南股份有限公司广州万博证券营业部。　　进一步统计，近3个月内该股累计发生15笔大宗交易，合计成交金额为2.21亿元。该股近5个交易日累计下跌5.53%，主力资金合计净流出1.3亿元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-03-03/doc-inenkmnh6633129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","03759","BK1141","BK0216","300759"],"gpt_icon":0},{"id":"2516683654","title":"昭衍新藥(06127)截至2月末累計回購A股股份326.98萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683654","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683654?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 16:57","pubTimestamp":1740992257,"startTime":"0","endTime":"0","summary":"昭衍新药(06127)发布公告，2025年2月，公司未回购A股股份。截至2025年...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1141","159982","BK0216","BK1576","399300","06127","603127"],"gpt_icon":0},{"id":"2516157074","title":"【黑石擬收購日本臨牀研究機構CMIC六成權益 或涉及數億美元】全球最大另類資產管理人黑石正收購一家專注於幫助製藥公司在日本進行臨牀試驗的公司CMIC Co.，反映其對日本老齡化人口健康需求的興趣日益增加。據悉，黑石同意收購CMIC Co. 60%股權，惟未有透露具體金額，僅指交易的價值可達數億美元。黑石日本私募股權主管Atsuhiko Sakamoto曾在訪問中表示，日本的臨牀試驗過程效率頗低，對比其他市場需時非常長。它們目前將簡化過程，可以更快介紹新藥到日本，而黑石可以從中作出貢獻。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516157074","media":"金融界","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516157074?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 14:39","pubTimestamp":1740983998,"startTime":"0","endTime":"0","summary":"全球最大另类资产管理人黑石正收购一家专注于帮助制药公司在日本进行临床试验的公司CMIC Co.，反映其对日本老龄化人口健康需求的兴趣日益增加。据悉，黑石同意收购CMIC Co. 60%股权，惟未有透露具体金额，仅指交易的价值可达数亿美元。黑石日本私募股权主管Atsuhiko Sakamoto曾在访问中表示，日本的临床试验过程效率颇低，对比其他市场需时非常长。它们目前将简化过程，可以更快介绍新药到日本，而黑石可以从中作出贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03143948480931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","IE00B64PRP62.GBP","BK4588","BK4135","BK1229","BX","03347","BK1574","BK1258","BK1583","IE00BN8TJ469.HKD","IE00BGHQF748.EUR","01477","BK1191","BK1542","IE0004445239.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","BK1141","IE00B3QW5Z07.USD","BK4585","09983"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":6,"totalSize":210}]}}